Table 1.
Characteristics of patients in the present study [n(%)]
| Variables | Total (n = 45) | ADPGK low expression (n = 19, 42.2%) | ADPGK high expression (n = 26, 57.8%) | P |
|---|---|---|---|---|
| Age (years) | 0.206 | |||
| < 70 | 14 (31.1) | 8 (42.1) | 6 (23.1) | |
| ≥ 70 | 31 (68.9) | 11 (57.9) | 20 (76.9) | |
| BMI (kg/m2) | 1.000 | |||
| < 25 | 30 (66.7) | 13 (68.4) | 17 (65.4) | |
| ≥ 25 | 15 (33.3) | 6 (31.6) | 9 (34.6) | |
| Baseline PSA (ng/ml) | 0.764 | |||
| < 20 | 21 (46.7) | 8 (42.1) | 13 (50.0) | |
| ≥ 20 | 24 (53.3) | 11 (57.9) | 13 (50.0) | |
| Neoadjuvant ADT | 0.024 | |||
| No | 32 (71.1) | 17 (89.5) | 15 (57.7) | |
| Yes | 13 (28.9) | 2 (10.5) | 11 (42.3) | |
| pT stage | 1.000 | |||
| < pT3 | 21 (46.7) | 9 (47.4) | 12 (46.2) | |
| ≥ pT3 | 24 (53.3) | 10 (52.6) | 14 (53.8) | |
| GS | 0.371 | |||
| < 8 | 27 (60.0) | 13 (68.4) | 14 (53.8) | |
| ≥ 8 | 18 (40.0) | 6 (31.6) | 12 (46.2) | |
| EPE | 1.000 | |||
| − | 21 (46.7) | 9 (47.4) | 12 (46.2) | |
| + | 24 (53.3) | 10 (52.6) | 14 (53.8) | |
| SVI | 0.507 | |||
| − | 32 (71.1) | 15 (78.9) | 17 (65.4) | |
| + | 13 (28.9) | 4 (21.1) | 9 (34.6) | |
| PNI | 0.341 | |||
| − | 13 (28.9) | 7 (36.8) | 6 (23.1) | |
| + | 32 (71.1) | 12 (63.2) | 20 (76.9) | |
| PSM | 0.734 | |||
| − | 12 (26.7) | 6 (31.6) | 6 (23.1) | |
| + | 33 (73.3) | 13 (68.4) | 20 (76.9) | |
| ADT | 0.770 | |||
| No | 20 (44.4) | 9 (47.4) | 11 (42.3) | |
| Yes | 25 (55.6) | 10 (52.6) | 15 (57.7) | |
| Adjuvant radiotherapy | 0.371 | |||
| No | 27 (60.0) | 13 (68.4) | 14 (53.8) | |
| Yes | 18 (40.0) | 6 (31.6) | 12 (46.2) | |
| Post RARP 3-month-PSA (ng/ml) | 0.764 | |||
| < 0.003 | 10 (22.2) | 5 (26.3) | 5 (19.2) | |
| 0.003–0.200 | 26 (57.8) | 11 (57.9) | 15 (57.7) | |
| > 0.200 | 9 (20.0) | 3 (15.8) | 6 (23.1) | |
ADPGK ADP-dependent glucokinase, BMI body mass index, PSA prostate specific antigen, ADT androgen deprivation therapy, pT pathologic T, GS Gleason score, EPE extraprostatic extension, SVI seminal vesicle invasion, PNI perineural invasion, PSM positive surgical margin